Comparison of nephrotoxicity of Colistin with Polymyxin B administered in currently recommended doses: a prospective study

Ritesh Aggarwal1* and Arun Dewan2

Abstract
Background: The most important concern with polymyxins (Colistin and Polymyxin B) use is nephrotoxicity. There is no prospective data comparing nephrotoxicity of these two drugs, when administered in high doses and as per current recommendations. We conducted a prospective study to compare their trend of nephrotoxicity in our patient population.

Methods: Our study included adult ICU patients who received more than 48 h of Colistin or Polymyxin B and had no confounding factors for nephrotoxicity. Loading and maintenance doses were given as per a uniform protocol. Nephrotoxicity was defined as twofold increase in serum creatinine, or 50% decrease in estimated baseline creatinine clearance. Patients were followed up for 1 week after therapy. Statistical analysis was performed using SPSS version 20.0.

Results: 61 patients were included in Colistin group, and 51 patients in Polymyxin B group. Median Colistin dose was 233.3 (IQR 150–300) mg/day and median Polymyxin B dose was 200 (IQR 180–240) mg/day. Median duration of Colistin and Polymyxin B use was 7 (IQR 5–7) days and 7 (IQR 7–9) days respectively. Nephrotoxicity developed in 39.3% patients in Colistin group compared to 11.8% patients in Polymyxin B group. Mean onset of nephrotoxicity was 3.8 ± 0.8 days with Colistin, and 4.2 ± 0.7 days with Polymyxin B therapy. In bivariate analysis, Colistin daily dose ≥ 300 mg was found to be associated with nephrotoxicity. There was no effect of age or BMI on Colistin toxicity. Mean duration of renal failure was 4.9 ± 3.1 days with Colistin use, and 5.0 ± 2.4 days with Polymyxin B use. 75% patients in Colistin group and 83.3% patients in Polymyxin B group who developed nephrotoxicity recovered their renal function by 1 week.

Conclusions: Colistin in currently recommended doses is significantly more nephrotoxic than Polymyxin B. Colistin toxicity is dose-dependent, mostly mild to moderate, and is reversible in most cases.

Keywords: Colistin, Polymyxin B, Nephrotoxicity, Acute kidney injury

Background
With the increasing incidence of multi-drug resistant (MDR) Gram negative infections, the focus has shifted to older antibiotics like polymyxins (Polymyxin E or Colistin and Polymyxin B) as agents of last resort [1]. Our recent understanding in the use of polymyxins is based on pharmacokinetic studies, which suggest a strategy of giving a loading dose, followed by higher intermittent doses at longer intervals [2, 3].

One of the major concern with the use of polymyxins is the risk of nephrotoxicity. The risk is further increased if they are used in higher doses. The reported rates of nephrotoxicity with polymyxins range from 15 to 60% [4–8]. Most of these studies have evaluated Colistin toxicity, and studies on Polymyxin B are very few. One of the reason for such a broad range of nephrotoxicity rates is the wide variation in doses of Colistin (and polymyxin)
used in different studies. Also, most studies were retrospective and had a limited number of patients. There is no available data comparing nephrotoxicity of Colistin and Polymyxin B when they are used as per current recommendations. A recent prospective study [9] found Colistin to be significantly more nephrotoxic compared to Polymyxin B. However, most of the study patients in Colistin group and all the patients in Polymyxin B group did not receive a loading dose. The results were also confounded by use of second nephrotoxic drug in majority of patients.

The purpose of our study was to prospectively compare the nephrotoxicity of these two drugs, when used in optimum doses and explore associated risk factors in our patient population.

**Methods**

**Design**

We conducted a prospective, observational study from July 2016 to June 2017 in a 16-bed medical ICU, in a tertiary care hospital. The study was approved by Ethics committee and was granted a waiver for informed consent.

**Patients**

We included all adult patients who received Colistin or Polymyxin B for more than 72 h. Exclusion criteria were (i) baseline CKD patient on hemodialysis or baseline creatinine clearance < 10 ml/min (estimated by Cockcroft Gault equation). (ii) Fluctuating renal parameters (increase or decrease in serum creatinine > 50% from baseline prior to starting polymyxins). (iii) Patient received intravenous contrast. (iv) Patient on any other nephrotoxic drug (aminoglycosides, vancomycin, amphotericin B, NSAIDs, cyclosporine, etc.). (v) Patient who received significant doses of diuretics (defined as furosemide > 20 mg or torsemide > 10 mg over 24 h). If the patient received two or more courses of polymyxins, only the first course was included in the study.

The choice of drug (Colistin vs Polymyxin B) was left to the treating physician. Once the drug was chosen, the loading and subsequent doses were given as per the institutional protocol (Table 1). Same brands of two drugs were used in all patients.

**Measurements/data collection**

In our study, nephrotoxicity or renal failure was defined as twofold increase in serum creatinine, or 50% decrease in estimated baseline creatinine clearance (Cockcroft Gault equation). Criteria were required to be fulfilled for at least 2 consecutive determinations 24 h apart, 48 h after starting Colistin or Polymyxin B. This corresponded to injury (I) class of RIFLE classification [10]. We didn’t include risk (R) class in our definition, as it is susceptible to various factors present in critically ill patients, and thus may not reflect the injury caused due to a nephrotoxic drug [11, 12]. We did not use urine output criteria to define nephrotoxicity. As suggested by acute dialysis quality initiative (ADQI) group, oliguria is a less

---

**Table 1: Dosing schedule for Colistin and Polymyxin B**

| Renal function                        | Loading dose                        | Maintenance dose                      |
|---------------------------------------|-------------------------------------|---------------------------------------|
| Normal renal function, creatinine     | 5 mg/kg (or 150,000 U/kg) IV over 40–60 min | 2.5 mg/kg (or 75,000 U/kg) IV twice daily |
| clearance > 50 ml/min                 |                                      |                                        |
| Creatinine clearance 20–50 ml/min     |                                      |                                        |
| Creatinine clearance < 20 ml/min      |                                      |                                        |
| Patient on hemodialysis               |                                      |                                        |

**Note**

1. Use ideal body weight for Colistin dosing, and not actual body weight
2. Maintenance doses are started 12 h after loading dose

**Dosing schedule for Polymyxin B in adults**

| Loading dose: 2.5 mg/kg as 2 h IV infusion | Maintenance dose: 1.5 mg/kg as 1 h IV infusion, twice daily |
|-------------------------------------------|-----------------------------------------------------------|

**Note**

1. Use actual body weight for Polymyxin B dosing
2. Maintenance doses are started 12 h after loading dose
3. There is no dose modification in renal failure
consistent marker of acute kidney injury (AKI), compared to serum creatinine levels [10].

The association of different variables (age, gender, BMI, APACHE 2, DM, and dose) with nephrotoxicity was analysed. For the analysis of relationship between Colistin dose and nephrotoxicity, the daily dose being administered to patient at the time he met criteria for nephrotoxicity was used. Serum creatinine levels were measured daily for a minimum of 7 days after the course of drugs was over. Reversal of nephrotoxicity was defined as return of serum creatinine to less than or equal to 2 times of baseline creatinine or greater than 50% of baseline creatinine clearance.

Statistical methods
The analysis of the data was done primarily by bivariate logistic regression to find the odds ratios of various factors, their confidence intervals and the statistical significance. Significance of the mean difference between groups for quantitative variables such as age, BMI and APACHE2 score was obtained by Student t-test after checking the equality of variances by Levene’s test. Student t-test was applied as our group sizes were sufficiently large. However, median and IQR were used for durations in view of their highly skewed distribution. In this case, the significance was tested by Wilcoxon test. Association between two qualitative factors was assessed using Chi square test for sufficiently large cell frequencies (n) and by Fisher exact test for small cell frequencies. For all the tests, the significance level was 5%. Statistical analysis was performed using SPSS version 20.0 (IBM, USA).

Results
A total of 210 patients were identified for eligibility. Of the 116 patients identified in Colistin (COL) group, 61 met inclusion criteria. Of the 94 patients identified in the Polymyxin B group (PMB), 51 met inclusion criteria. The primary reason for ineligibility in both groups were use of second nephrotoxic drug (like intravenous contrast, aminoglycosides, amphotericin B, and diuretics infusion) of second nephrotoxic drug (like intravenous contrast, aminoglycosides, amphotericin B, and diuretics infusion) and presence of end stage renal disease (ESRD).

The site of infection was lungs in 66 (58.9%), urinary tract in 19 (17.0%), blood stream in 10 (8.9%) and abdomen in 9 (8.0%) patients. The pathogens were isolated in 77 (68.7%) patients and include Klebsiella (27.7%), Pseudomonas (17.0%), Acinetobacter (19.6%) and E. coli (4.5%). There was no growth on cultures in 35 (31.2%) patients (Table 2).

There were no significant differences in two groups with respect to baseline demographics or underlying risk factors for nephrotoxicity (Table 1). Mean estimated creatinine clearance for Colistin (COL) and Polymyxin B (PMB) group were 60.8 ± 33.5 and 55.4 ± 31.6 ml/min respectively. The median daily dose was 233.3 mg (IQR 150–300) in COL group and 200 mg (IQR 180–240) for PMB group.

All patients in Colistin group received a loading dose followed by maintenance doses starting at 12 h, as per institutional protocol (Table 1). Doses were modified according to ideal body weight and estimated creatinine clearance (Cockcroft Gault equation). Serum creatinine values were measured daily and in case of acute kidney injury, doses were modified as per creatinine clearance estimation. Colistin was withheld only if patient developed significant metabolic acidosis or hyperkalemia or needed hemodialysis.

All patients in Polymyxin B group (PMB), similarly, received a loading dose followed by maintenance doses based on actual body weight. There was no dose modification as per estimated creatinine clearance. Polymyxin B was not used in suspected or confirmed cases of urinary tract infection (UTI), due to its poor penetration in urinary tract. Median drug duration was 7 (IQR 5–7) days for Colistin and 7 (IQR 7–9) days for Polymyxin B.

The overall incidence of nephrotoxicity in all patients was 26.8% (30 of 112 patients). The incidence of nephrotoxicity was significantly higher in Colistin group (39.3%) compared to Polymyxin B group (11.8%) (P < 0.001). If we compare the incidence of renal failure as per RIFLE criteria, the incidence of risk, injury, failure—all classes combined was 52.4% in Colistin group and 19.6% in Polymyxin B group (P < 0.001). Mean onset of renal failure was 3.8 ± 0.8 days in COL group and 4.2 ± 0.7 days in PMB group. Mean duration of kidney injury was 4.9 ± 3.1 days in COL group and 5.0 ± 2.4 days in PMB group. 9 patients (14.7%) in COL group required hemodialysis and drug discontinuation. In comparison, only 1 patient (2%) in PMB group required hemodialysis and drug discontinuation.

We followed up all the patients for 1 week after the completion of course of antibiotics or drug discontinuation to understand the trends of nephrotoxicity. At the end of 1 week, there was reversal of nephrotoxicity in 75% of patients (18 of 24) in COL group. In PMB group, there was reversal in 83.3% (5 of 6) patients who had developed renal failure. In other words, at the end of 1 week follow up, 9.8% patients in COL group had renal failure, compared to 2% patients in PMB group. The primary and secondary outcomes have been shown in Table 3.

The subgroup analysis of Colistin group has been shown in Table 4. Among the patients of this group, patients who received a daily dose of ≥300 mg (or ≥9 million international units) had higher incidence of renal failure (17 of 27, 63.0%) (P = 0.001) (OR 6.56). We also observed that incidence of renal failure was significantly less in patients whose baseline creatinine clearance was
Table 2 Patient characteristics in 2 groups

| Variable                  | Colistin (n = 61) | Polymyxin B (n = 51) | P value |
|---------------------------|-------------------|----------------------|---------|
| Gender, male              | 39 (63.9)         | 36 (70.6)            | 0.456   |
| Age (years)               | 64.3 ± 13.3       | 63.4 ± 17.1          | 0.769   |
| Weight (kg)               | 73.2 ± 11.8       | 69.3 ± 13.4          | 0.106   |
| BMI (kg/m²)               | 26.8 ± 4.3        | 25.0 ± 4.7           | 0.041   |
| APACHE 2 score           | 20.8 ± 4.2        | 22.0 ± 4.6           | 0.167   |
| Baseline creatinine clearance (ml/min) | 60.8 ± 33.5       | 55.4 ± 31.6          | 0.382   |
| DM                        | 30 (49.2)         | 22 (43.1)            | 0.523   |
| HTN                       | 12 (19.7)         | 11 (21.6)            | 0.071   |
| Use of vasopressors       | 39 (63.9)         | 28 (54.9)            | 0.381   |
| Number of days of antibiotic use [median(IQR)] | 7 (5–7)           | 7 (7–9)              | 0.221   |
| Median daily dose (mg)    | 233.3 (150–300)   | 200 (180–240)        | 0.116   |
| Site of infection (mg)    |                   |                      |         |
| Lungs                     | 28 (45.9)         | 38 (74.5)            | 0.002   |
| Urine                     | 19 (31.1)         | 0 (0)                | < 0.001 |
| Bloodstream               | 5 (8.2)           | 5 (9.8)              | 0.766   |
| Abdomen                   | 5 (8.2)           | 4 (7.8)              | 0.945   |
| Others                    | 4 (6.5)           | 4 (7.8)              | 0.792   |
| Pathogens                 |                   |                      |         |
| Klebsiella                | 19 (31.1)         | 12 (23.5)            | 0.370   |
| Pseudomonas               | 8 (13.1)          | 11 (21.6)            | 0.235   |
| Acinetobacter             | 12 (19.7)         | 10 (19.6)            | 0.993   |
| E. coli                   | 4 (6.5)           | 1 (2)                | 0.241   |
| No growth                 | 18 (29.5)         | 17 (33.3)            | 0.664   |

Data are presented as n (%), or mean ± SD or median (IQR)

low, i.e.<50 ml/min (5 of 28, 17.9%) than in patients with creatinine clearance ≥ 50 ml/min (19 of 33, 57.6%) (P = 0.002). The post hoc analysis of these patients revealed that patients with lower creatinine clearance received less daily dose of Colistin (150 mg, IQR 150–233.3), compared to those with higher creatinine clearance (300 mg, IQR 291.6–333.3) (P < 0.05). The difference in nephrotoxicity can, thus, be attributed to dose.

There was no effect of diabetes, age and BMI on Colistin nephrotoxicity. A striking observation in our study was the presence of higher incidence of renal failure in patients with lower APACHE 2 score (14 of 27, 51.9%) compared to higher APACHE 2 score (10 of 34, 29.4%), although this was not statistically significant (P = 0.075). It is very unlikely that greater degree of sickness in any patient will confer any degree of protection against Colistin nephrotoxicity. When we did post hoc analysis of these patients, we found that patients in higher APACHE group received lower Colistin dose (233.3 mg, IQR 191.6–283.3) compared to patients in lower APACHE group (300 mg, IQR 166.7–308.3). Bivariate analysis of risk factors for Colistin induced nephrotoxicity has been shown in Table 5.

Among patients who developed renal failure with Colistin, 75% (18 of 24) had recovery from renal failure by 1 week. On subgroup analysis, there was no significant effect of Age, BMI, dose, or baseline creatinine clearance on reversal of Colistin toxicity (Table 6).

Out of 51 patients in PMB group, only 6 (11.8%) developed nephrotoxicity. Interestingly, out of these 6 patients, 5 patients (83.3%) had baseline renal dysfunction, i.e. creatinine clearance < 50 ml/min. There was no effect of any other factor on Polymyxin B nephrotoxicity. There was recovery from nephrotoxicity in 83.3% (5 of 6) patients by 1 week.

Discussion

In our study, use of Colistin was associated with significantly higher nephrotoxicity as compared to Polymyxin B. The patients in two groups of our study were similar in baseline demographics, comorbidities, APACHE 2 score, baseline creatinine clearance. And thus, it is unlikely that difference in any of these factors affected the results.

The incidence of nephrotoxicity in our study was 39.3% with Colistin and 11.8% with Polymyxin B. Nephrotoxicity was defined as greater than or equal to two-fold rise in serum creatinine value or 50% decline in estimated creatinine clearance. This corresponds to injury (I) and failure (F) classes of RIFLE classification. Published literature has shown significant variability in nephrotoxicity rates with polymyxin drugs. Recent studies [4–8] have reported renal failure rates of 17–60% with Colistin. A most recent prospective study has shown renal failure rates of 16.9% with Colistin [9].

There are multiple reasons for these discrepancies in the reported rates of nephrotoxicity. Different studies
have used different criteria to define nephrotoxicity. Even when RIFLE criteria were used, ‘risk (R)’ category was included as part of renal injury in some studies [4, 5, 7, 8] while it was excluded in other studies [6]. In a recent study, only failure (F) category was used to define renal failure [9]. Another source of discrepancy is the presence of additional confounding factors contributing to renal failure [6, 9]. In the recent study by Rigatto et al. 84% of patients in Colistin group and 71% of patients in Polymyxin B group received a second nephrotoxic drug (aminoglycosides, vancomycin, intravenous contrast) [9]. Similarly, in the study by Dalfino et al. 50% patients in Colistin group additionally received aminoglycosides [6].

Different dosing regimens have been used in different studies, and are likely to have contributed to variations in nephrotoxicity rates. As per most recent recommendations based on pharmacokinetic principles, Colistin is recommended to be administered as a loading dose followed 12 h later as maintenance doses [2]. Different studies have used Colistin in different dosing schedules. Patients within a study have received different Colistin doses. Colistin loading has not been used in many studies [4, 6, 7]. In the study by Rigatto et al. only 27% patients in Colistin group received a loading dose [9]. Similarly, there are recommendations for no dose adjustment for Polymyxin B according to creatinine clearance [3]. The low rates of nephrotoxicity with Polymyxin B in

| Subgroup | Nephrotoxicity | Difference | 95% CI | P value |
|----------|---------------|------------|--------|--------|
| DM       | Yes           | No         | 0.05   | 0.30 to 0.19 | 0.674 |
|          | 11 (36.7)     | 13 (41.9)  |        |        |
| Baseline Cr clearance (ml/min) | ≥ 50 | < 50 | 0.40 | 0.18 to 0.62 | 0.002 |
|          | 19 (57.6)     | 5 (17.9)   |        |        |
| Age      | ≥ 65 | < 65 | 0.12 | 0.13 to 0.37 | 0.348 |
|          | 12 (46.2)     | 8 (38.1)   |        |        |
| BMI      | ≥ 30 | < 30 | 0.02 | 0.28 to 0.24 | 0.885 |
|          | 8 (38.1)      | 16 (40.0)  |        |        |
| APACHE 2 score | ≥ 20 | < 20 | 0.22 | 0.47 to 0.02 | 0.075 |
|          | 10 (29.4)     | 14 (51.9)  |        |        |
| Total daily dose | ≥ 300 mg | < 300 mg | 0.42 | 0.20 to 0.65 | 0.001 |
|          | 17 (63.0)     | 7 (20.6)   |        |        |

Table 5 Predictors of Colistin nephrotoxicity

| Variable | Bivariate analysis | OR | 95% CI | P value |
|----------|-------------------|----|--------|---------|
| BMI ≥ 30 |                    | 0.92 | 0.31 to 2.73 | 0.885 |
| DM (yes) |                   | 0.80 | 0.29 to 2.24  | 0.802 |
| Age ≥ 65 |                   | 1.64 | 0.58 to 4.65  | 0.350 |
| Daily dose ≥ 300 mg/day |               | 6.56 | 2.10 to 20.52 | 0.001 |
| APACHE ≥ 20 |                        | 0.39 | 0.13 to 1.11  | 0.387 |
| Baseline creatinine clearance < 50 ml/min | 0.16 | 0.05 to 0.53 | 0.003 |

Table 6 Subgroup analysis of reversal of Colistin nephrotoxicity

| Subgroup | Nephrotoxicity | Difference | 95% CI | P value |
|----------|---------------|------------|--------|--------|
| DM       | Yes           | No         | 0.13   | 0.21 to 0.46 | 0.478 |
|          | 9 (81.8)      | 9 (69.2)   |        |        |
| Baseline creatinine clearance (ml/min) | ≥ 50 | < 50 | 0.19 | 0.28 to 0.66 | 0.384 |
|          | 15 (78.9)     | 3 (60)     |        |        |
| Age      | ≥ 65 | < 65 | 0    | 0.35 to 0.35 | 1.000 |
|          | 9 (75.0)      | 9 (75.0)   |        |        |
| BMI      | ≥ 30 | < 30 | 0.52 | 0.84 to (−0.21) | 0.064 |
|          | 8 (100)       | 10 (62.5)  |        |        |
| Total daily dose | ≥ 300 mg | < 300 mg | 0.05 | 0.34 to 0.44 | 0.795 |
|          | 13 (76.5)     | 5 (71.4)   |        |        |
Polymyxin B was 4 (mean 4.2 doses used in these patients. We do not feel that the load-
lower creatinine clearance (OR 0.16, 95% CI 0.05–0.53, P=0.003) (Table 4), and this was likely due to lower
doses used in these patients. We do not feel that the loading dose of Colistin is responsible for its toxicity, because
patients in lower (daily) Colistin dose group received similar loading doses. Some studies have found an asso-
ciation between total cumulative dose of Colistin and its toxicity [18, 19]. However, in our study, the vast major-
ity of nephrotoxicity occurred with first 4 days of therapy, and thus no association between cumulative dose and
toxicity was observed.

We, thus, found that Colistin nephrotoxicity was related to amount of daily maintenance dose and was not
related to loading dose or cumulative total dose. Higher maintenance doses of Colistin have been recommended
to optimize serum concentrations, and thus antibiotic efficacy [2]. Does this mean that present recommenda-
tions of maintenance dosing need further optimization to reduce its nephrotoxicity? Larger pharmacokinetic—
based studies are needed to answer this question.

19 patients in Colistin group (out of 61) had urinary tract infection (UTI). On analysing these 19 patients, we
found that 2 patients had upper urinary tract infections (pyelonephritis), while the remaining 17 patients had
lower urinary tract infections. Presence of upper urinary tract infection can, per se, lead to kidney injury. How-
ever, we feel that it was not a significant confounding fac-
tor in our findings, because of following reasons. First, we excluded patients who had fluctuating (improving or
worsening) renal parameters prior to starting Colistin or Polymyxin B. Second, even after starting Polymyxin B or
Colistin, nephrotoxicity criteria were required to be ful-
filled for at least 2 consecutive determinations 24 h apart,
48 h after starting the drug. Finally, “risk” category of RIFLE classification was excluded from our definition of
nephrotoxicity, which is most affected by any such con-
founding factor.

The reversal of nephrotoxicity has not been reported in most of the earlier studies. Dewan et al. reported that
all patients who developed renal failure had reversal by 8 days and no patient required dialysis [8]. In our study,
a significant number of patients (75%) who developed Colistin toxicity had a reversal by 1 week. We did not find
any significant factor contributing to this reversal.

In the polymyxin group, a striking observation was that most patients who developed nephrotoxicity were those
who had a baseline renal dysfunction (creatine clearance less than 50 ml/min). Since, polymyxin dosing is not
affected by creatinine clearance, these patients had also received similar doses as patients with normal creatinine
clearance [3]. Sandri et al. found that renal clearance is a minor elimination pathway in case of Polymyxin B, and
hence they recommended no dose reduction in renal dys-
function. But they observed that reduced renal elimina-
tion is basically due to extensive tubular reabsorption,
and this tubular reabsorption contributes to its nephro-
toxicity. Thus, it is likely that, in a patient with lower
creatine clearance, the ‘fewer’ functioning nephrons are exposed to relatively ‘large’ dose of Polymyxin B, when no dose reduction is done. In other words, it is likely that, unlike Colistin, where there is an overlap between therapeutic doses and toxicity doses, in case of Polymyxin B, there is a gap between the two. Toxicity thus manifests only in patients with compromised renal function, who get exposed to “significantly” large doses. Does this mean that polymyxin dosing also needs reduction in renal failure? We need larger prospective studies on Polymyxin B nephrotoxicity to answer this question.

Our study was limited by smaller number of patients in two groups. Some of our observations might have been affected by smaller group size. Also, we did not measure serum Colistin levels, which would have given more insights into its pharmacokinetics and its relationship with nephrotoxicity. Finally, we followed up our patients for 1 week after stopping the drug. Extending the follow up period to 6–8 weeks could have given better understanding of recovery of nephrotoxicity.

To conclude, our study showed that Colistin is more nephrotoxic than Polymyxin B. We also observed that dose is the principal factor contributing to Colistin nephrotoxicity. Nephrotoxicity is mostly mild to moderate and reversible. Larger studies are needed to confirm our observations.

Abbreviations
COL: Colistin; PMB: Polymyxin B; BMI: body mass index; CKD: chronic kidney disease; IQR: inter quartile range; MDR: multi-drug resistant; ADQI: acute dialysis quality initiative; AKI: acute kidney injury; APACHE: acute physiology and chronic health evaluation.

Authors’ contributions
RA collected, and analyzed the patients’ data. Both RA and AD were involved in interpretation of data. Both had major contribution in writing of the manuscript. Both authors read and approved the final manuscript.

Author details
1 Department of Critical Care Medicine, Max Smart Super Speciality Hospital, Saket, New Delhi, India. 2 Department of Internal Medicine & Critical Care Medicine, Max Smart Super Speciality Hospital, Saket, New Delhi, India.

Acknowledgements
The authors would like to acknowledge Dr. Abhaya Indrayan, Department of Medical Statistics, Max Hospital, for his contribution to statistical analysis.

Competing interests
The authors declare that they have no competing interests.

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author (Ritesh Aggarwal) on reasonable request.

Consent for publication
Not applicable.

Ethics approval and consent to participate
Ethics approval and approval for waiver of informed consent was taken from Ethics Committee, Max Smart Super Speciality Hospital, New Delhi.

Funding
The authors declare that there was no source of funding.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 14 September 2017 Accepted: 8 March 2018
Published online: 23 March 2018

References
1. Nation RL, Velkov T, Li J. Colistin and Polymyxin B: peas in a pod, or chalk and cheese? Clin Infect Dis. 2014;59:88–94.
2. Garonzik SM, Li J, Thamlilitikul V, Paterson DL, Shoham S, Jacob J, Silveira FP, Forrest A, Nation RL. Population pharmacokinetics of Colistin methanesulfonate and formed Colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother. 2011;55:3284–94.
3. Sandri AM, Landersdorfer CB, Jacob J, Boniatti MA, Dalarosa MG, Falci DR, Behle TF, Bordinhao RC, Wang J, Forrest A, Nation RL, Li J, Zavascki AP. Population pharmacokinetics of intravenous Polymyxin B in critically ill patients: implications for selection of dosage regimens. Clin Infect Dis. 2013;57:524–31.
4. Phe K, Lee Y, McDannel PM, Prasad N, Yin T, Figueroa DA, Musick WL, Cottreau JM, Hu M, Tam VH. In vitro assessment and multicentre cohort study of comparative nephrotoxicity rates associated with colistimethate versus Polymyxin B therapy. Antimicrob Agents Chemother. 2014;58:2740–6.
5. Akajagbor DS, Wilson SL, Shere-Wolfe KD, Dukum P, Charurat ME, Gilliam BL. Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with Polymyxin B in critically ill patients at a tertiary care medical center. Clin Infect Dis. 2013;57:1300–3.
6. Dalfino L, Puntillo F, Onodjak M, Mosca A, Monno R, Coppolecchia S, Spada ML, Bruno F, Brienzo N. Colistin-associated acute kidney injury in severely ill patients: a step toward a better renal care? A prospective cohort study. Clin Infect Dis. 2015;61:1771–7.
7. Balkan II, Dogan M, Durdu B, Batirel A, Hakyemez IN, Cetin B, et al. Colistin nephrotoxicity increases with age. Scand J Infect Dis. 2014;46:678–85.
8. Dewan A, Shoukat M. Evaluation of risk of nephrotoxicity with high dose, extended-interval Colistin administration. Indian J Crit Care Med. 2014;18(7):427–30.
9. Rigatto MH, Oliveira MS, Perdigao-Neto LV, Levin AS, Carrilho CM, Tanita MT, Tuon FF, Cardoso DE, Lopes NT, Falci DR, Zavascki AP. Multicenter prospective cohort study of renal failure in patients treated with Colistin versus Polymyxin B. Antimicrob Agents Chemother. 2016;60:2443–9.
10. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute renal failure—definition, outcome measures, animal models, fluid therapy and information technology needs: the second international consensus conference of the acute dialysis quality initiative (ADQI) group. Crit Care. 2004;8:R204–12.
11. Cruz DN, Ricci Z, Ronco C. Clinical review: RIFLE and AKIN—time for reappraisal. Crit Care. 2009;13:211.
12. Hoste EA, Clermont G, Kersten A, Venkataraman SR, Angus DC, De Bacquer D, Kellum JA. RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: a cohort analysis. Crit Care. 2006;10:R73.
13. Oliveira MS, Prado GV, Costa SF, Grinbaum RS, Levin AS. Polymyxin B and colistimethate are comparable as to efficacy and renal toxicity. Diagn Microbiol Infect Dis. 2009;65:431–4.
14. Deryke CA, Crawford AJ, Uddin N, Wallace MR. Colistin dosing and nephrotoxicity in a large community teaching hospital. Antimicrob Agents Chemother. 2010;54:4503–5.
15. Pogue JM, Lee J, Marchaim D, Yee V, Zhao JJ, Chopra T, et al. Incidence of and risk factors for Colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis. 2011;53:879–84.
16. Javan O, Shokouhi S, Sahraei Z. A review on Colistin nephrotoxicity. Eur J Clin Pharmacol. 2015;71(7):801–10.
17. Zavascki AP, Nation RL. Nephrotoxicity of polymyxins: is there any difference between colistimethate and Polymyxin B? Antimicrob Agents Chemother. 2017;61(3):e02319-16.
18. Hartzell JD, Neff R, Ake J, et al. Nephrotoxicity associated with intravenous Colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis. 2009;48:1724–8.
19. Sorli L, Luque S, Grau S, Berenguer N, Segura C, Montero MM, Alvarez-Lerma F, Knobel H, Benito N, Horcajada JP. Trough Colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study. BMC Infect Dis. 2013;13:380.